Zimmermann Milan, Fandrich Madeleine, Jakobi Meike, Röben Benjamin, Wurster Isabel, Lerche Stefanie, Schulte Claudia, Zimmermann Shahrzad, Deuschle Christian, Schneiderhan-Marra Nicole, Joos Thomas O, Gasser Thomas, Brockmann Kathrin
Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), University of Tuebingen, Tuebingen, Germany.
NPJ Parkinsons Dis. 2025 Jun 13;11(1):166. doi: 10.1038/s41531-025-00984-3.
Parkinson's disease (PD) exhibits substantial phenotypic variability, likely influenced, at least in part, by proteins associated with pathways integral to aging processes. Plasminogen activator inhibitor-1 (SERPIN E1) is known for its association with aging processes and exacerbated α-Synuclein pathology. We examined whether SERPIN E1 levels in cerebrospinal fluid (CSF) differ among controls (CON, N = 16) and patients with PD (N = 479) or Dementia with Lewy bodies (DLB, N = 67), considering that these conditions represent a spectrum of α-Synuclein pathology. Kaplan-Meier survival analysis stratified by SERPIN E1 tertile levels was conducted to evaluate phenotype-modifying effects. Elevated levels of SERPIN E1 exhibited an association with increased age and lower MOCA scores. Heightened SERPIN E1 levels were observed in individuals diagnosed with DLB, followed by PD and CON, and in males compared to females. The quantification of SERPIN E1 in CSF could potentially serve as a surrogate marker, depicting (pathological) aging processes.
帕金森病（PD）表现出显著的表型变异性，这可能至少部分受到与衰老过程所必需的途径相关的蛋白质的影响。纤溶酶原激活物抑制剂-1（SERPIN E1）因其与衰老过程以及加剧的α-突触核蛋白病理学的关联而闻名。鉴于这些病症代表了α-突触核蛋白病理学的一个范围，我们研究了对照组（CON，N = 16）、帕金森病患者（N = 479）或路易体痴呆（DLB，N = 67）的脑脊液（CSF）中SERPIN E1水平是否存在差异。进行了按SERPIN E1三分位数水平分层的Kaplan-Meier生存分析，以评估表型修饰作用。SERPIN E1水平升高与年龄增加和较低的蒙特利尔认知评估（MOCA）得分相关。在被诊断为DLB的个体中观察到SERPIN E1水平升高，其次是PD和CON，并且男性高于女性。脑脊液中SERPIN E1的定量可能潜在地作为一种替代标志物，描绘（病理）衰老过程。
